Patents by Inventor Seiichi UCHIMURA
Seiichi UCHIMURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250091006Abstract: Provided is an isolation and purification method for isolating and purifying extracellular vesicles. In the method for isolating and purifying extracellular vesicles from a solution containing the extracellular vesicles and unnecessary substances. The isolation and purification method is an adsorbent treatment method in which a solution containing the extracellular vesicles and unnecessary substances is brought into contact with an adsorbent to cause the adsorbent to adsorb and retain the unnecessary substances other than the extracellular vesicles. The adsorbent is a porous granular material having a pore, an interior of the pore being positively charged, and the adsorbent can adsorb and retain, in the interior of the pore, negatively charged unnecessary substances other than the extracellular vesicles.Type: ApplicationFiled: January 10, 2023Publication date: March 20, 2025Applicants: Daicel Corporation, DAICEN MEMBRANE-SYSTEMS Ltd.Inventors: Shuji NAKATSUKA, Seiichi UCHIMURA, Takahiro OCHIYA, Yusuke YOSHIOKA
-
Patent number: 12202858Abstract: The purpose of the present invention is to provide a solid-phase carrier on which an IgG-binding peptide is immobilized, the peptide being usable for IgG purification, having resistance to repeated washing with an alkaline solution after IgG purification, and having a high binding affinity for IgG. Specifically, the present invention relates to a solid-phase carrier on which an IgG-binding peptide is immobilized, wherein the two cysteine residues on the outside of the peptide are linked as shown in the following formula: (in the formula, the upper cysteine residue is on the N-terminal side of the peptide, and the lower cysteine residue is on the C-terminal side of the peptide).Type: GrantFiled: October 7, 2019Date of Patent: January 21, 2025Assignees: KAGOSHIMA UNIVERSITY, DAICEL CORPORATIONInventors: Yuji Ito, Seiichi Uchimura
-
Patent number: 12195498Abstract: Provided is a separating agent that does not have a significantly reduced dynamic binding capacity (DBC) to a target substance even when the separating agent is continually CIP-treated under alkaline pH conditions. The separating agent includes a carrier and a protein, wherein the protein is a given protein, and a surface of the carrier and a lysine residue in the protein are bound by a chemical bond.Type: GrantFiled: July 1, 2019Date of Patent: January 14, 2025Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATIONInventors: Yoichi Kumada, Hiromichi Okura, Seiichi Uchimura
-
Patent number: 12103948Abstract: Provided is a separating agent with an improved dynamic binding capacity (DBC) to a target substance. The separating agent includes a carrier and a protein, wherein the protein is a given protein, and a surface of the carrier and added lysine residues in the protein are bound by chemical bonds.Type: GrantFiled: July 1, 2019Date of Patent: October 1, 2024Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATIONInventors: Yoichi Kumada, Hiromichi Okura, Seiichi Uchimura
-
Publication number: 20240238728Abstract: [Object] To provide an isolation and purification method for isolating and purifying extracellular vesicles. [Solution] An isolation and purification method of extracellular vesicles is disclosed. A hollow fiber membrane has an inner diameter of 0.2 mm to 1.4 mm and a molecular weight cut-off of 100000 to 1000000. Filtering includes a first filtration process of press-fitting the culture supernatant of the mesenchymal stem cells from a first opening on one end side of the hollow fiber membrane and filtering the culture supernatant to separate the culture supernatant into a permeate and a first concentrate, and a second filtration process of press-fitting the first concentrate from a second opening on the other end side of the hollow fiber membrane and filtering the first concentrate to separate the first concentrate into a permeate and a second concentrate.Type: ApplicationFiled: May 24, 2022Publication date: July 18, 2024Applicants: DAICEN MEMBRANE-SYSTEMS Ltd., Daicel CorporationInventors: Shuji NAKATSUKA, Seiichi UCHIMURA, Takahiro OCHIYA, Yusuke YOSHIOKA
-
Patent number: 11643474Abstract: An object of the present invention is to provide a method by which a peptide having a specific binding capability that can be used for purification of a target molecule can be produced at a low cost, and specifically relates to a peptide fusion protein including one or more peptides having specific binding capability and a scaffold protein, the peptide being inserted into the amino acid sequence of the scaffold protein directly or via a peptide linker, and/or being linked to the N-terminal and/or C-terminal of the scaffold protein.Type: GrantFiled: August 1, 2019Date of Patent: May 9, 2023Assignees: KAGOSHIMA UNIVERSITY, DAICEL CORPORATIONInventors: Yuji Ito, Seiichi Uchimura, Hiromichi Okura
-
Publication number: 20220127304Abstract: Provided is a separating agent that does not have a significantly reduced dynamic binding capacity (DBC) to a target substance even when the separating agent is continually CIP-treated under alkaline pH conditions. The separating agent includes a carrier and a protein, wherein the protein is a given protein, and a surface of the carrier and a lysine residue in the protein are bound by a chemical bond.Type: ApplicationFiled: July 1, 2019Publication date: April 28, 2022Applicants: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATIONInventors: Yoichi KUMADA, Hiromichi OKURA, Seiichi UCHIMURA
-
Publication number: 20210380637Abstract: The purpose of the present invention is to provide a solid-phase carrier on which an IgG-binding peptide is immobilized, the peptide being usable for IgG purification, having resistance to repeated washing with an alkaline solution after IgG purification, and having a high binding affinity for IgG. Specifically, the present invention relates to a solid-phase carrier on which an IgG-binding peptide is immobilized, wherein the two cysteine residues on the outside of the peptide are linked as shown in the following formula: (in the formula, the upper cysteine residue is on the N-terminal side of the peptide, and the lower cysteine residue is on the C-terminal side of the peptide).Type: ApplicationFiled: October 7, 2019Publication date: December 9, 2021Applicants: KAGOSHIMA UNIVERSITY, DAICEL CORPORATIONInventors: Yuji ITO, Seiichi UCHIMURA
-
Patent number: 11186613Abstract: The present invention provides an IgG-binding peptide which can be used for the purification of IgG and has excellent stability, e.g., alkali stability. The present invention also provides a method for purifying IgG using the IgG-binding peptide. Specifically, the present invention relates to a solid-phase support including an IgG-binding peptide, an IgG separation column including the solid-phase support, a kit including the solid-phase support or the column, and a method for purifying IgG using the solid-phase support or the column.Type: GrantFiled: November 17, 2017Date of Patent: November 30, 2021Assignees: Kagoshima University, Daicel CorporationInventors: Yuji Ito, Seiichi Uchimura
-
Publication number: 20210332152Abstract: An object of the present invention is to provide a method by which a peptide having a specific binding capability that can be used for purification of a target molecule can be produced at a low cost, and specifically relates to a peptide fusion protein including one or more peptides having specific binding capability and a scaffold protein, the peptide being inserted into the amino acid sequence of the scaffold protein directly or via a peptide linker, and/or being linked to the N-terminal and/or C-terminal of the scaffold protein.Type: ApplicationFiled: August 1, 2019Publication date: October 28, 2021Applicants: KAGOSHIMA UNIVERSITY, DAICEL CORPORATIONInventors: Yuji ITO, Seiichi UCHIMURA, Hiromichi OKURA
-
Patent number: 11136609Abstract: An object of the present invention is to provide a separation agent for separating a human serum-derived IgG polyclonal antibody. This object is achieved by a separation agent for separating a human serum-derived IgG polyclonal antibody, the separation agent including: a carrier; and a single-chain antibody which has a dissociation constant for a human serum-derived IgG polyclonal antibody of not more than 3.0×10?8 M and which binds to the surface of the carrier via a chemical bond.Type: GrantFiled: November 7, 2016Date of Patent: October 5, 2021Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATIONInventors: Yoichi Kumada, Yuya Hasegawa, Seiichi Uchimura
-
Publication number: 20210269476Abstract: Provided is a separating agent with an improved dynamic binding capacity (DBC) to a target substance. The separating agent includes a carrier and a protein, wherein the protein is a given protein, and a surface of the carrier and added lysine residues in the protein are bound by chemical bonds.Type: ApplicationFiled: July 1, 2019Publication date: September 2, 2021Applicants: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATIONInventors: Yoichi KUMADA, Hiromichi OKURA, Seiichi UCHIMURA
-
Publication number: 20190367560Abstract: The present invention provides an IgG-binding peptide which can be used for the purification of IgG and has excellent stability, e.g., alkali stability. The present invention also provides a method for purifying IgG using the IgG-binding peptide. Specifically, the present invention relates to a solid-phase support including an IgG-binding peptide, an IgG separation column including the solid-phase support, a kit including the solid-phase support or the column, and a method for purifying IgG using the solid-phase support or the column.Type: ApplicationFiled: November 17, 2017Publication date: December 5, 2019Applicants: Kagoshima University, Daicel CorporationInventors: Yuji Ito, Seiichi Uchimura
-
Publication number: 20180327803Abstract: An object of the present invention is to provide a separation agent for separating a human serum-derived IgG polyclonal antibody. This object is achieved by a separation agent for separating a human serum-derived IgG polyclonal antibody, the separation agent including: a carrier; and a single-chain antibody which has a dissociation constant for a human serum-derived IgG polyclonal antibody of not more than 3.0×10?8 M and which binds to the surface of the carrier via a chemical bond.Type: ApplicationFiled: November 7, 2016Publication date: November 15, 2018Applicants: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATIONInventors: Yoichi KUMADA, Yuya HASEGAWA, Seiichi UCHIMURA